Suppr超能文献

P-糖蛋白过表达无法解释大鼠胶质母细胞瘤细胞系中完全的阿霉素耐药表型。

P-glycoprotein overexpression cannot explain the complete doxorubicin-resistance phenotype in rat glioblastoma cell lines.

作者信息

Huet S, Schott B, Robert J

机构信息

Fondation Bergonié, Bordeaux, France.

出版信息

Br J Cancer. 1992 Apr;65(4):538-44. doi: 10.1038/bjc.1992.111.

Abstract

We have associated pharmacological studies to a semi-quantitative evaluation of P-glycoprotein(s) expression, to establish if classical multidrug resistance (MDR) could account for the complete resistance phenotype exhibited by progressively doxorubicin-resistant rat glioblastoma cells. Three resistant variants (C6 0.001, C6 0.1 and C6 0.5) of the C6 glioblastoma cell line (C6 S) were selected by long-term culture in the presence of three concentrations of doxorubicin (0.001, 0.1 and 0.5 microgram.ml-1 respectively). The degree of doxorubicin resistance was respectively 7, 33 and 400, and all the cell variants were cross-resistant to m-AMSA, etoposide and vincristine. Doxorubicin incorporation was reduced similarly in all resistant cells, irrespective of the level of resistance. When exposed to their respective doxorubicin IC50, the 7-fold resistant cells had the same intracellular drug incorporation as the sensitive cells, whereas the 33-fold and 400-fold resistant cells could incorporate respectively 3.7 and 17 times more drug. The ratio of doxorubicin exposures required for 50% DNA synthesis inhibition and 50% growth inhibition was dependent on the degree of resistance; this ratio was 12.8 in C6 S, 11.6 in C6 0.001, 6.3 in C6 0.1 and 1.8 in C6 0.5. P-glycoprotein(s) overexpression was of the same magnitude as the resistance factor in variants C6 0.001 and C6 0.1, but was lower than resistance factor in variant C6 0.5. Reversal of drug incorporation by verapamil was complete in all resistant cell lines; however, reversal of doxorubicin cytotoxicity was complete only in the 7-fold resistant line and was only partial in the most resistant lines, which remained 10-fold and 20-fold resistant to doxorubicin. These results suggest that classical MDR was the first phenotype selected by doxorubicin in C6 0.001, whereas mechanism(s) of doxorubicin resistance other than classical MDR are added in the most resistant lines.

摘要

我们将药理学研究与P-糖蛋白表达的半定量评估相关联,以确定经典多药耐药性(MDR)是否能解释逐渐对阿霉素耐药的大鼠胶质母细胞瘤细胞所表现出的完全耐药表型。通过在三种浓度的阿霉素(分别为0.001、0.1和0.5微克·毫升-1)存在下长期培养,从C6胶质母细胞瘤细胞系(C6 S)中筛选出三个耐药变体(C6 0.001、C6 0.1和C6 0.5)。阿霉素耐药程度分别为7倍、33倍和400倍,所有细胞变体对m-AMSA、依托泊苷和长春新碱均有交叉耐药性。无论耐药水平如何,所有耐药细胞中阿霉素的摄取均类似地减少。当暴露于各自的阿霉素IC50时,7倍耐药细胞的细胞内药物摄取量与敏感细胞相同,而33倍和400倍耐药细胞分别可摄取多3.7倍和17倍的药物。50%DNA合成抑制和50%生长抑制所需的阿霉素暴露比值取决于耐药程度;该比值在C6 S中为12.8,在C6 0.001中为11.6,在C6 0.1中为6.3,在C6 0.5中为1.8。P-糖蛋白的过表达程度与变体C6 0.001和C6 0.1中的耐药因子相同,但低于变体C6 0.5中的耐药因子。维拉帕米对所有耐药细胞系中药物摄取的逆转均是完全的;然而,阿霉素细胞毒性的逆转仅在7倍耐药细胞系中是完全的,在耐药性最强的细胞系中只是部分逆转,这些细胞系对阿霉素仍有10倍和20倍的耐药性。这些结果表明,经典MDR是阿霉素在C6 0.001中选择的第一种表型,而在耐药性最强的细胞系中增加了除经典MDR之外的阿霉素耐药机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16dc/1977580/86a116fce28e/brjcancer00068-0057-a.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验